Physiogenex will be exhibiting at booth#D04 and presenting 2 oral abstracts at the EASD 2022 in Stockholm, Sweden Sept. 19-23.
The first oral presentation, entitled “Time-restricted feeding and obeticholic acid/semaglutide drug combination have a different impact on non-alcoholic steatohepatitis in diet-induced obese mice” will be delivered by Dr. François Briand, our Director of Research and Development, on Wednesday Sept. the 21st, 2:30pm-4pm.
The second oral presentation, entitled “Gut microbiome: a link between autonomic neuropathy and kidney disease in diabetes?” will be delivered by Dr. Estelle Grasset, Project Manager at Physiogenex, our expert in obesity/type 2 diabetes, neuropathy and microbiome, on Friday Sept. the 23rd, 12:45pm-1:15pm.
Come visit our booth #D04 in the exhibition area or contact us if you wish to set-up an appointment with Dr. Briand and Dr. Estelle Grasset during the EASD and/or discuss your drug development projects with us.
About us
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.